ISDA

Deposition Date 2024-12-12

Release Date 2025-05-28

Last Version Date 2025-06-04

Entry Detail

PDB ID:

9MID

Keywords:

IMMUNE SYSTEM

Title:

Crystal structure of the VRC01-class antibody 3G08, derived from GT1.1 vaccination, in complex with eOD-GT8

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)
Human immunodeficiency virus 1 (Taxon ID: 11676)

Host Organism:

Homo sapiens

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.74 Å

R-Value Free:

0.24

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Polymer Type:polypeptide(L)
Molecule:eOD-GT8 engineered mutant of gp120
Chain IDs:C
Chain Length:183
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1

Polymer Type:polypeptide(L)
Molecule:3G08 Fab Heavy Chain
Chain IDs:A (auth: H)
Chain Length:223
Number of Molecules:1
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Molecule:3G08 Fab Light Chain
Chain IDs:B (auth: L)
Chain Length:211
Number of Molecules:1
Biological Source:Homo sapiens

Ligand Molecules

NAG

Primary Citation

Precise targeting of HIV broadly neutralizing antibody precursors in humans.

Caniels, T.G, Prabhakaran, M, Ozorowski, G, MacPhee, K.J, Wu, W, van der Straten, K, Agrawal, S, Derking, R, Reiss, E.I.M.M, Millard, K, Turroja, M, Desrosiers, A, Bethony, J, Malkin, E, Liesdek, M.H, van der Veen, A, Klouwens, M, Snitselaar, J.L, Bouhuijs, J.H, Bronson, R, Jean-Baptiste, J, Gajjala, S, Rikhtegaran Tehrani, Z, Benner, A, Ramaswami, M, Duff, M.O, Liu, Y.W, Sato, A.H, Kim, J.Y, Baken, I.J.L, Mendes Silva, C, Bijl, T.P.L, van Rijswijk, J, Burger, J.A, Cupo, A, Yasmeen, A, Phulera, S, Lee, W.H, Randall Jr, K.N, Zhang, S, Corcoran, M.M, Regadas, I, Sullivan, A.C, Brown, D.M, Bohl, J.A, Greene, K.M, Gao, H, Yates, N.L, Sawant, S, Prins, J.M, Kootstra, N.A, Kaminsky, S.M, Barin, B, Rahaman, F, Meller, M, Philiponis, V, Laufer, D.S, Lombardo, A, Mwoga, L, Shotorbani, S, Holman, D, Koup, R.A, Klasse, P.J, Karlsson Hedestam, G.B, Tomaras, G.D, van Gils, M.J, Montefiori, D.C, McDermott, A.B, Hyrien, O, Moore, J.P, Wilson, I.A, Ward, A.B, Diemert, D.J, de Bree, G.J, Andrews, S.F, Caskey, M, Sanders, R.W.Show

Science ? eadv5572 eadv5572 (2025)

PMID: 40373114 DOI: 10.1126/science.adv5572

Abstact

A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. In a double-blinded, placebo-controlled phase 1 human clinical trial, the recombinant, germline-targeting envelope glycoprotein (Env) trimer BG505 SOSIP.v4.1-GT1.1, adjuvanted with AS01B, induced bnAb precursors of the VRC01-class at a high frequency in the majority of vaccine recipients. These bnAb precursors, that target the CD4 receptor binding site, had undergone somatic hypermutation characteristic of the VRC01-class. A subset of isolated VRC01-class monoclonal antibodies neutralized wild-type pseudoviruses and was structurally extremely similar to bnAb VRC01. These results further support germline-targeting approaches for human HIV vaccine design and demonstrate atomic-level manipulation of B cell responses with rational vaccine design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures